Last reviewed · How we verify

Thyroid-stimulating hormone secreting pituitary tumour — Treatment Landscape & Competitive Intelligence

Thyroid-stimulating hormone secreting pituitary tumour (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Thyroid-stimulating hormone secreting pituitary tumour, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Somatuline Depot LANREOTIDE Ipsen Pharma Somatostatin Analog Somatostatin receptor type 2 2007-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Ipsen Pharma · 1 drug in Thyroid-stimulating hormone secreting pituitary tumour

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Thyroid-stimulating hormone secreting pituitary tumour:

Cite this brief

Drug Landscape (2026). Thyroid-stimulating hormone secreting pituitary tumour — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/thyroid-stimulating-hormone-secreting-pituitary-tumour. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing